Strategic agreement between THX Pharma and Biocodex for three rare diseases

THX Pharma (Theranexus) has signed a licensing agreement with Biocodex, a company specializing in rare neurological diseases. Biocodex has been granted two licenses to develop Batten-1 globally and TX01 in North America, with a potential revenue of €173 million, including an initial €12 million. Batten-1 targets juvenile Batten disease, and TX01 is intended for Gaucher and Niemann-Pick type C diseases.

These conditions, often affecting children, cause serious neurological and hematological complications. The partnership combines THX Pharma's expertise with Biocodex's financial support to accelerate the clinical development of treatments. This project aims to address unmet medical needs in the field of rare genetic diseases.